

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

SECTION 1. IDENTIFICATION

Product name : Fluazuron / Abamectin Formulation

Manufacturer or supplier's details

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Flammable liquids : Category 3

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye
irritation : Category 2A

Skin sensitization : Category 1

Germ cell mutagenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity -
single exposure : Category 3

Specific target organ toxicity -
repeated exposure : Category 2 (Central nervous system)

Short-term (acute) aquatic
hazard : Category 1

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H226 Flammable liquid and vapor.
H302 + H332 Harmful if swallowed or if inhaled.
H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H336 May cause drowsiness or dizziness.
H341 Suspected of causing genetic defects.
H360D May damage the unborn child.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P333 + P313 If skin irritation or rash occurs: Get medical ad-

Fluazuron / Abamectin Formulation

Version 8.1 Revision Date: 24.03.2025 SDS Number: 803723-00026 Date of last issue: 06.07.2024
Date of first issue: 12.07.2016

vice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Vapors may form explosive mixture with air.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|---|-------------|-----------------------|
| Propan-2-ol | 67-63-0 | >= 30 -< 50 |
| N-Methyl-2-pyrrolidone | 872-50-4 | >= 30 -< 50 |
| Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy)- | 642443-86-5 | >= 20 -< 30 |
| Fluazuron | 86811-58-7 | >= 2,5 -< 5 |
| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2 | >= 1 -< 2,5 |
| 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate | 2386-87-0 | >= 1 -< 2,5 |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 | >= 0,1 -< 0,25 |

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

| | | |
|---|---|--|
| If swallowed | : | If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed or if inhaled. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. May cause respiratory irritation. May cause drowsiness or dizziness. Suspected of causing genetic defects. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

| | | |
|--|---|---|
| Suitable extinguishing media | : | Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : | High volume water jet |
| Specific hazards during fire fighting | : | Do not use a solid water stream as it may scatter and spread fire. Flash back possible over considerable distance. Vapors may form explosive mixtures with air. Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides Nitrogen oxides (NO _x) Chlorine compounds Fluorine compounds |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

| | | |
|---|---|---|
| Personal precautions, protective equipment and emergency measures | : | Remove all sources of ignition. Use personal protective equipment. |
|---|---|---|

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

-
- | | | |
|---|---|---|
| gency procedures | | Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : | Non-sparking tools should be used. Soak up with inert absorbent material. Suppress (knock down) gases/vapors/mists with a water spray jet. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |
-

SECTION 7. HANDLING AND STORAGE

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. Use explosion-proof electrical, ventilating and lighting equipment. |
| Advice on safe handling | : | Do not get on skin or clothing. Do not breathe mist or vapors. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Non-sparking tools should be used. Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Take precautionary measures against static discharges. |

Fluazuron / Abamectin Formulation

Version 8.1 Revision Date: 24.03.2025 SDS Number: 803723-00026 Date of last issue: 06.07.2024
 Date of first issue: 12.07.2016

- Do not eat, drink or smoke when using this product.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Keep tightly closed.
 Keep in a cool, well-ventilated place.
 Store in accordance with the particular national regulations.
 Keep away from heat and sources of ignition.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Self-reactive substances and mixtures
 Organic peroxides
 Flammable solids
 Pyrophoric liquids
 Pyrophoric solids
 Self-heating substances and mixtures
 Substances and mixtures which in contact with water emit flammable gases
 Explosives
 Gases
 Very acutely toxic substances and mixtures

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--|------------|--|--|----------|
| Propan-2-ol | 67-63-0 | CMP | 400 ppm | AR OEL |
| | | CMP - CPT | 500 ppm | AR OEL |
| | | TWA | 200 ppm | ACGIH |
| | | STEL | 400 ppm | ACGIH |
| Fluazuron | 86811-58-7 | TWA | 60 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 600 µg/ 100cm ² | Internal |
| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2 | TWA | 15 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 150 µg/100 cm ² | Internal |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 | CMP (Vapour and aerosol, inhalable fraction) | 2 mg/m ³ | AR OEL |
| Further information: A4 - Not classifiable as a human carcinogen | | | | |
| | | TWA (Inhalable fraction and vapor) | 2 mg/m ³ | ACGIH |

Fluazuron / Abamectin Formulation

Version 8.1 Revision Date: 24.03.2025 SDS Number: 803723-00026 Date of last issue: 06.07.2024
 Date of first issue: 12.07.2016

Biological occupational exposure limits

| Components | CAS-No. | Control parameters | Biological specimen | Sampling time | Permissible concentration | Basis |
|------------------------|----------|----------------------------------|---------------------|--|---------------------------|-----------|
| N-Methyl-2-pyrrolidone | 872-50-4 | 5-Hydroxy-N-methyl-2-pyrrolidone | Urine | End of shift (As soon as possible after exposure ceases) | 100 mg/l | ACGIH BEI |
| Propan-2-ol | 67-63-0 | Acetone | Urine | | 2 mg/g creatinine | AR BEI |
| | | Acetone | Urine | End of shift at end of work-week | 40 mg/l | ACGIH BEI |

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.
 Use explosion-proof electrical, ventilating and lighting equipment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving. Take note that the product is flammable, which may impact the selection of hand protection.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Hygiene measures : Use appropriate degowning techniques to remove potentially contaminated clothing.
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

| | |
|--|---------------------|
| Appearance | : liquid |
| Color | : No data available |
| Odor | : No data available |
| Odor Threshold | : No data available |
| pH | : No data available |
| Melting point/freezing point | : No data available |
| Initial boiling point and boiling range | : No data available |
| Flash point | : 28 °C |
| Evaporation rate | : No data available |
| Flammability (solid, gas) | : Not applicable |
| Flammability (liquids) | : Not applicable |
| Upper explosion limit / Upper flammability limit | : No data available |
| Lower explosion limit / Lower flammability limit | : No data available |
| Vapor pressure | : No data available |
| Relative vapor density | : No data available |
| Relative density | : No data available |
| Density | : No data available |

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

| | |
|--|--|
| Solubility(ies) | |
| Water solubility | : No data available |
| Partition coefficient: n-octanol/water | : Not applicable |
| Autoignition temperature | : No data available |
| Decomposition temperature | : No data available |
| Viscosity | |
| Viscosity, kinematic | : No data available |
| Explosive properties | : Not explosive |
| Oxidizing properties | : The substance or mixture is not classified as oxidizing. |
| Molecular weight | : No data available |
| Particle characteristics | |
| Particle size | : Not applicable |

SECTION 10. STABILITY AND REACTIVITY

| | |
|------------------------------------|---|
| Reactivity | : Not classified as a reactivity hazard. |
| Chemical stability | : Stable under normal conditions. |
| Possibility of hazardous reactions | : Flammable liquid and vapor. Vapors may form explosive mixture with air. Can react with strong oxidizing agents. |
| Conditions to avoid | : Heat, flames and sparks. |
| Incompatible materials | : Oxidizing agents |
| Hazardous decomposition products | : No hazardous decomposition products are known. |

SECTION 11. TOXICOLOGICAL INFORMATION

| | |
|--|--|
| Information on likely routes of exposure | : Inhalation Skin contact Ingestion Eye contact |
|--|--|

Acute toxicity

Harmful if swallowed or if inhaled.

Product:

| | |
|---------------------------|--|
| Acute oral toxicity | : Acute toxicity estimate: 1.822 mg/kg Method: Calculation method |
| Acute inhalation toxicity | : Acute toxicity estimate: 2,06 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method |

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Acute dermal toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:**Propan-2-ol:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 25 mg/l
Exposure time: 6 h
Test atmosphere: vapor

Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4.150 mg/kg
Method: OECD Test Guideline 401
Remarks: The test was conducted equivalent or similar to guideline

Acute inhalation toxicity : LC50 (Rat): > 5,1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: The test was conducted according to guideline

Acute dermal toxicity : LD50 (Rat): > 5.000 mg/kg
Method: OECD Test Guideline 402
Remarks: The test was conducted equivalent or similar to guideline

Poly[oxy(methyl-1,2-ethanediyl)], α -(1-oxotetradecyl)- ω -(phenylmethoxy)-:

Acute oral toxicity : LD50 (Rat): > 16.000 mg/kg

Fluazuron:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 6,0 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0,023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2.000 mg/kg

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Acute oral toxicity : LD50 (Rat, male): > 2.959 - 5.000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): >= 5,19 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 436
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:

Propan-2-ol:

Species : Rabbit
Result : No skin irritation

N-Methyl-2-pyrrolidone:

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation
Remarks : The test was conducted equivalent or similar to guideline

Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy)-:

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Species : Rabbit
Result : Mild skin irritation

Fluazuron:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : No skin irritation

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Propan-2-ol:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

N-Methyl-2-pyrrolidone:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405
Remarks : The test was conducted equivalent or similar to guideline

Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy)-:

Species : Rabbit
Result : No eye irritation

Fluazuron:

Species : Rabbit
Result : Mild eye irritation
Method : OECD Test Guideline 405

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Result : Mild eye irritation

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

May cause an allergic skin reaction.

Respiratory sensitization

Not classified based on available information.

Components:**Propan-2-ol:**

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative

N-Methyl-2-pyrrolidone:

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative
Remarks : Based on data from similar materials

Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy)-:

Test Type : Human repeat insult patch test (HRIPT)
Routes of exposure : Skin contact
Result : negative

Fluazuron:

Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximization Test
Routes of exposure : Skin contact

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Result : Not a skin sensitizer.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : positive

Assessment : Probability or evidence of skin sensitization in humans

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)
Routes of exposure : Skin contact
Species : Humans
Result : negative

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:**Propan-2-ol:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: The test was conducted according to guideline

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: The test was conducted according to guideline

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Method: OECD Test Guideline 482
Result: negative
Remarks: The test was conducted equivalent or similar to guideline

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Method: OECD Test Guideline 474
 Result: negative
 Remarks: The test was conducted according to guideline

Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy)-:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Fluazuron:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: DNA Repair
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Cytogenetic assay
 Species: Hamster
 Result: equivocal

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster lung cells
 Result: negative

Test Type: Alkaline elution assay
 Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
 Species: Mouse
 Application Route: Intraperitoneal injection
 Result: negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Method: OECD Test Guideline 471
 Result: positive

Test Type: In vitro mammalian cell gene mutation test
 Result: positive

Test Type: In vitro sister chromatid exchange assay in mam-

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

- malian cells
Result: positive
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive
- Genotoxicity in vivo : Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 486
Result: negative
- Test Type: Micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative
- Test Type: Transgenic rodent somatic cell gene mutation assay
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 488
Result: positive
- Germ cell mutagenicity - Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.
- 2,6-Di-tert-butyl-p-cresol:**
- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Result: negative
- Test Type: Chromosome aberration test in vitro
Result: negative
- Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Propan-2-ol:**

- Species : Rat
Application Route : inhalation (vapor)
Exposure time : 104 weeks

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Method : OECD Test Guideline 451
Result : negative

N-Methyl-2-pyrrolidone:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 451
Result : negative
Remarks : The test was conducted according to guideline

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : negative
Remarks : The test was conducted equivalent or similar to guideline

Fluazuron:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : negative

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Mouse
Application Route : Skin contact
Exposure time : 29 Months
Result : negative

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**Propan-2-ol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

N-Methyl-2-pyrrolidone:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: The test was conducted according to guideline

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted according to guideline

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapor)
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Fluazuron:

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0,12 mg/kg body weight
Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight
Developmental Toxicity: NOAEL: 0,2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects., Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1,6 mg/kg body weight
Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

experiments.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

May cause respiratory irritation.
May cause drowsiness or dizziness.

Components:**Propan-2-ol:**

Assessment : May cause drowsiness or dizziness.

N-Methyl-2-pyrrolidone:

Assessment : May cause respiratory irritation.

STOT-repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Routes of exposure : Ingestion
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Routes of exposure : Ingestion
Target Organs : nasal cavity
Assessment : Shown to produce significant health effects in animals at concentrations of >10 to 100 mg/kg bw.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

tions of 100 mg/kg bw or less.

Repeated dose toxicity**Components:****Propan-2-ol:**

| | |
|-------------------|----------------------|
| Species | : Rat |
| NOAEL | : 12,5 mg/l |
| Application Route | : inhalation (vapor) |
| Exposure time | : 104 Weeks |

N-Methyl-2-pyrrolidone:

| | |
|-------------------|---|
| Species | : Rat, male |
| NOAEL | : 169 mg/kg |
| LOAEL | : 433 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 90 Days |
| Method | : OECD Test Guideline 408 |
| Remarks | : The test was conducted according to guideline |

| | |
|-------------------|---|
| Species | : Rat |
| NOAEL | : 0,5 mg/l |
| LOAEL | : 1 mg/l |
| Application Route | : inhalation (dust/mist/fume) |
| Exposure time | : 96 Days |
| Method | : OECD Test Guideline 413 |
| Remarks | : The test was conducted according to guideline |

| | |
|-------------------|---|
| Species | : Rabbit, male |
| NOAEL | : 826 mg/kg |
| LOAEL | : 1.653 mg/kg |
| Application Route | : Skin contact |
| Exposure time | : 20 Days |
| Method | : OECD Test Guideline 410 |
| Remarks | : The test was conducted equivalent or similar to guideline |

Fluazuron:

| | |
|-------------------|-----------------------------------|
| Species | : Rat |
| LOAEL | : 240 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 13 Weeks |
| Target Organs | : Liver, Thyroid, Pituitary gland |

| | |
|-------------------|----------------|
| Species | : Rat |
| NOAEL | : 10 mg/kg |
| LOAEL | : 100 mg/kg |
| Application Route | : Skin contact |
| Exposure time | : 3 Weeks |

| | |
|---------|-------------|
| Species | : Dog |
| NOAEL | : 7,5 mg/kg |
| LOAEL | : 110 mg/kg |

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

| | |
|-------------------|-------------|
| Application Route | : Ingestion |
| Exposure time | : 52 Weeks |
| Target Organs | : Liver |

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

| | |
|-------------------|--------------------------|
| Species | : Rat |
| NOAEL | : 1,5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 24 Months |
| Target Organs | : Central nervous system |
| Symptoms | : Tremors, ataxia |

| | |
|-------------------|--------------------------|
| Species | : Mouse |
| NOAEL | : 4,0 mg/kg |
| Application Route | : Oral |
| Exposure time | : 24 Months |
| Target Organs | : Central nervous system |
| Symptoms | : Tremors, ataxia |

| | |
|-------------------|--------------------------|
| Species | : Dog |
| NOAEL | : 0,25 mg/kg |
| LOAEL | : 0,5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 53 Weeks |
| Target Organs | : Central nervous system |
| Symptoms | : Tremors, weight loss |
| Remarks | : mortality observed |

| | |
|-------------------|--------------------------|
| Species | : Monkey |
| NOAEL | : 1,0 mg/kg |
| Application Route | : Oral |
| Exposure time | : 14 Weeks |
| Target Organs | : Central nervous system |

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

| | |
|-------------------|---------------------------|
| Species | : Rat |
| NOAEL | : 5 mg/kg |
| LOAEL | : 50 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 90 Days |
| Method | : OECD Test Guideline 408 |

2,6-Di-tert-butyl-p-cresol:

| | |
|-------------------|-------------|
| Species | : Rat |
| NOAEL | : 25 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 22 Months |

Aspiration toxicity

Not classified based on available information.

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:

Skin contact : Symptoms: Skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Propan-2-ol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9.640 mg/l
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 10.000 mg/l
aquatic invertebrates Exposure time: 24 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1.050 mg/l
Exposure time: 16 h

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 1.000 mg/l
aquatic invertebrates Exposure time: 24 h
Method: DIN 38412
Remarks: The test was conducted according to guideline

Toxicity to algae/aquatic : ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l
plants Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l
Exposure time: 72 h

Toxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): 12,5 mg/l
aquatic invertebrates (Chron- Exposure time: 21 d
ic toxicity) Method: OECD Test Guideline 211
Remarks: The test was conducted according to guideline

Toxicity to microorganisms : EC50 (activated sludge): > 600 mg/l
Exposure time: 30 min
Method: ISO 8192
Remarks: The test was conducted according to guideline

Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy)-:

Toxicity to fish : LC50 : 540 mg/l

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Exposure time: 96 h
Test substance: Water Accommodated Fraction

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 221 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction

Toxicity to algae/aquatic plants : NOEC (Selenastrum capricornutum (fresh water algae)): 78 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Fluazuron:

Toxicity to fish : LC50 (Cyprinus carpio (Carp)): > 9,1 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia sp. (Water flea)): 0,0006 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : NOEC (Raphidocelis subcapitata (freshwater green algae)): 27,9 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 1.000

M-Factor (Chronic aquatic toxicity) : 1.000

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3,2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9,6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0,022 µg/l
Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0,34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10.000

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

icity)
Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,52 µg/l
Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,03 µg/l
Exposure time: 21 d
NOEC (Mysidopsis bahia (opossum shrimp)): 0,0035 µg/l
Exposure time: 28 d

M-Factor (Chronic aquatic toxicity) : 10.000
Toxicity to microorganisms : EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 24 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 40 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 110 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Raphidocelis subcapitata (freshwater green alga)): 30 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC10 (activated sludge): 409 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0,57 mg/l
Exposure time: 96 h
Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,48 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0,24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,24

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1
Toxicity to fish (Chronic toxicity) : NOEC (Oryzias latipes (Japanese medaka)): 0,053 mg/l
Exposure time: 30 d
Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,316 mg/l
Exposure time: 21 d
M-Factor (Chronic aquatic toxicity) : 1
Toxicity to microorganisms : EC50: > 10.000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Propan-2-ol:**

Biodegradability : Result: rapidly degradable
BOD/COD : BOD: 1,19 (BOD5)
COD: 2,23
BOD/COD: 53 %

N-Methyl-2-pyrrolidone:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C
Remarks: The test was conducted according to guideline

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 71 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 4,5 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Bioaccumulative potential**Components:****Propan-2-ol:**

Partition coefficient: n-octanol/water : log Pow: 0,05

N-Methyl-2-pyrrolidone:Partition coefficient: n-octanol/water : log Pow: -0,46
Method: OECD Test Guideline 107
Remarks: The test was conducted according to guideline**Fluazuron:**

Partition coefficient: n-octanol/water : log Pow: 5,1

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:Partition coefficient: n-octanol/water : log Pow: 1,34
Method: OECD Test Guideline 107**2,6-Di-tert-butyl-p-cresol:**Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1.800

Partition coefficient: n-octanol/water : log Pow: 5,1

Mobility in soil**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3,6

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

| | |
|------------------------|--|
| Waste from residues | : Do not dispose of waste into sewer. Dispose of in accordance with local regulations. |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal. Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other |

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

sources of ignition. They may explode and cause injury and/or death.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

| | |
|---------------------------|---|
| UN number | : UN 1993 |
| Proper shipping name | : FLAMMABLE LIQUID, N.O.S. (Propan-2-ol) |
| Class | : 3 |
| Packing group | : III |
| Labels | : 3 |
| Environmentally hazardous | : no |

IATA-DGR

| | |
|--|---|
| UN/ID No. | : UN 1993 |
| Proper shipping name | : Flammable liquid, n.o.s. (Propan-2-ol) |
| Class | : 3 |
| Packing group | : III |
| Labels | : Flammable Liquids |
| Packing instruction (cargo aircraft) | : 366 |
| Packing instruction (passenger aircraft) | : 355 |

IMDG-Code

| | |
|----------------------|--|
| UN number | : UN 1993 |
| Proper shipping name | : FLAMMABLE LIQUID, N.O.S. (Propan-2-ol, Fluazuron, abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| Class | : 3 |
| Packing group | : III |
| Labels | : 3 |
| EmS Code | : F-E, <u>S-E</u> |
| Marine pollutant | : yes |

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

| | |
|---|------------------|
| Argentina. Carcinogenic Substances and Agents Registry. | : Not applicable |
|---|------------------|

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

Control of precursors and essential chemicals for the : Propan-2-ol
preparation of drugs.

The ingredients of this product are reported in the following inventories:

| | |
|-------|------------------|
| AICS | : not determined |
| DSL | : not determined |
| IECSC | : not determined |

SECTION 16. OTHER INFORMATION

| | |
|---------------|--------------|
| Revision Date | : 24.03.2025 |
| Date format | : dd.mm.yyyy |

Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD
compile the Material Safety eChem Portal search results and European Chemicals Agen-
Data Sheet cy, <http://echa.europa.eu/>

Full text of other abbreviations

| | |
|-----------|---|
| ACGIH | : USA. ACGIH Threshold Limit Values (TLV) |
| ACGIH BEI | : ACGIH - Biological Exposure Indices (BEI) |
| AR BEI | : Argentina. Biological Exposure Indices |
| AR OEL | : Argentina. Occupational Exposure Limits |

| | |
|--------------------|---------------------------------|
| ACGIH / TWA | : 8-hour, time-weighted average |
| ACGIH / STEL | : Short-term exposure limit |
| AR OEL / CMP | : TLV (Threshold Limit Value) |
| AR OEL / CMP - CPT | : STEL (Short Term Limit Value) |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumu-

Fluazuron / Abamectin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 06.07.2024 |
| 8.1 | 24.03.2025 | 803723-00026 | Date of first issue: 12.07.2016 |

lative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8